Class III β-Tubulin Overexpression Induces Chemoresistance to Eribulin in a Leiomyosarcoma Cell Line

Eribulin is a new drug to treat soft tissue sarcoma (STS) that exerts antitumor activity by binding to microtubules. The prognosis of STS is poor, and eribulin is expected to improve the treatment outcome. We observed several cases that exhibited resistance to eribulin and developed an eribulin-resi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Anal Cell Pathol (Amst)
Main Authors: Yahiro, Kenichiro, Matsumoto, Yoshihiro, Fukushi, Jun-ichi, Kawaguchi, Ken-ichi, Endo, Makoto, Setsu, Nokitaka, IIda, Keiichiro, Fukushima, Suguru, Nakagawa, Makoto, Kimura, Atsushi, Oda, Yoshinao, Nakashima, Yasuharu
Formato: Artigo
Idioma:Inglês
Publicado em: Hindawi 2018
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6033248/
https://ncbi.nlm.nih.gov/pubmed/30034996
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2018/8987568
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Accesso online

https://ncbi.nlm.nih.gov/pmc/articles/PMC6033248/
https://ncbi.nlm.nih.gov/pubmed/30034996
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2018/8987568